Skip to main content

Table 2 Rates and reasons for discontinuation

From: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

  Etanercept cohort (N = 2725)
Discontinuations 1655 (60.7)
Remission 652 (23.9)
Inefficacy 594 (21.8)
Intolerance 192 (7.1)
Patient’s demand 504 (18.5)
Others 287 (10.5)
  1. Data are shown as n (%). Multiple reasons could be given